- Home
- MYGN vs ZGN Comparison
MYGN vs ZGN Comparison
Compare MYGN & ZGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- ZGN
- Stock Information
- Founded
- MYGN 1991
- ZGN 1910
- Country
- MYGN United States
- ZGN Italy
- Employees
- MYGN N/A
- ZGN N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ZGN Apparel
- Sector
- MYGN Health Care
- ZGN Consumer Discretionary
- Exchange
- MYGN Nasdaq
- ZGN Nasdaq
- Market Cap
- MYGN 744.7M
- ZGN 2.0B
- IPO Year
- MYGN 1995
- ZGN N/A
- Fundamental
- Price
- MYGN $5.60
- ZGN $9.15
- Analyst Decision
- MYGN Hold
- ZGN Buy
- Analyst Count
- MYGN 15
- ZGN 2
- Target Price
- MYGN $15.14
- ZGN $8.05
- AVG Volume (30 Days)
- MYGN 1.6M
- ZGN 1.9M
- Earning Date
- MYGN 08-05-2025
- ZGN 03-27-2025
- Dividend Yield
- MYGN N/A
- ZGN 1.54%
- EPS Growth
- MYGN N/A
- ZGN N/A
- EPS
- MYGN N/A
- ZGN 0.31
- Revenue
- MYGN $831,300,000.00
- ZGN $2,015,371,157.00
- Revenue This Year
- MYGN N/A
- ZGN $0.74
- Revenue Next Year
- MYGN $6.68
- ZGN $4.74
- P/E Ratio
- MYGN N/A
- ZGN $29.46
- Revenue Growth
- MYGN 7.38
- ZGN 2.21
- 52 Week Low
- MYGN $3.81
- ZGN $6.05
- 52 Week High
- MYGN $29.30
- ZGN $11.69
- Technical
- Relative Strength Index (RSI)
- MYGN 59.81
- ZGN 63.83
- Support Level
- MYGN $4.90
- ZGN $8.24
- Resistance Level
- MYGN $5.74
- ZGN $8.99
- Average True Range (ATR)
- MYGN 0.27
- ZGN 0.32
- MACD
- MYGN 0.10
- ZGN -0.01
- Stochastic Oscillator
- MYGN 85.71
- ZGN 86.32
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About ZGN Ermenegildo Zegna N.V.
Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of its revenue from the Zegna segment.